COMPANY:

Ibex Medical Analytics

"Ibex Medical Analytics (Ibex)...today unveiled the latest advancements in its innovative product platform. These new features, developed in collaboration with expert pathologists around the world who use the product in routine clinical practice, underscore Ibex’s commitment to creating tools that meet the needs of those on the frontline of patient care."

"Ibex Medical Analytics (Ibex)...announced the publication of a clinical study evaluating Ibex's Galen platform, published in the peer-reviewed journal Pathology, which demonstrated excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies.... During the study, Galen Prostate demonstrated high accuracy in detecting prostate adenocarcinoma with an Area Under the Curve (AUC) of 0.988. The AI algorithm was also highly accurate in cancer grading, specifically differentiating between low and medium/high-grade Gleason scores with an AUC of 0.994, as well as in identifying perineural invasion. In several cases, Galen Prostate's AI algorithm accurately identified higher Gleason scores than previously evaluated by a pathologist and unveiled previously undetected cancer, showcasing its potential to enhance diagnostic accuracy and reduce inter-observer variability."

"These studies, highlighting the value of Ibex's AI-powered cancer diagnostics...A study conducted at Brigham and Women's Hospital and Champalimaud Foundation evaluated Galen Breast's performance in identifying microinvasive carcinoma of the breast in a challenging patient cohort. Microinvasive carcinoma is defined as the focus of invasive breast cancer no larger than 1mm, in which accurate detection has important implications for patient management. The results indicate that Galen Breast's AI algorithm is highly accurate in detecting microinvasive lesions and has the potential to improve consistency in diagnosis and support more efficient workflows in pathology laboratories...The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting, with NPV and PPV of 0.99....Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755."

"Dedalus Group...and Ibex Medical Analytics...announced the launch of a fully integrated End-to-End AI-powered Digital Pathology Solution for cancer diagnosis."

"Ibex Medical Analytics...announced it has earned certified status by HITRUST for information security...HITRUST Risk-based, 2-year (r2) Certified status demonstrates that Ibex and Galen™, its AI-powered pathology platform, have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk."

"Roche...announced today collaborations with Ibex Medical Analytics and Amazon Web Services, enabling pathology laboratories to access Ibex’s AI-powered decision support tools to support clinicians in breast and prostate cancer diagnosis through the navify^® Digital Pathology software platform."

"Ibex Medical Analytics (Ibex)...and CorePlus Servicios Clínicos y Patológicos...announced CorePlus has diagnosed over 10,000 cases using Galen™, Ibex’s AI-powered cancer diagnostics platform. In a significant boost to patient outcomes, pathologists used AI-driven insights from Galen to correct the diagnosis of over 150 patients."

"Ibex Medical Analytics (Ibex)...announced the launch of Galen™ Breast HER2, an AI-powered solution that aids pathologists in setting a higher standard for accurate and reproducible HER2 (human epidermal growth factor receptor 2) scoring in breast cancer patients."

"Ibex Medical Analytics (Ibex)...announced it has closed a $55 million Series C financing round led by 83North. Additional participants in the round were Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100 million since Ibex's inception in 2016."